Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma

Table 1

Baseline characteristics of HCC patients for the entire study.

Variable		N = 79
		n	%
Gender	Male	74	93.7
	Female	5	6.3
Age (years)	>50	47	59.5
	≤50	32	40.5
CTC count	>1	42	53.2
	≤1	37	46.8
Tumor number	>3	15	19.0
	≤3	64	81.0
Tumor diameter (cm)	>3	31	39.2
	≤3	48	60.8
PVT	Yes	16	20.3
	No	63	79.7
MVI	Yes	15	19.0
	No	64	81.0
Edmonson stage	I-II	48	60.8
	III-IV	31	39.2
Liver cirrhosis	Yes	73	92.4
	No	6	7.6
Milan criteria	Yes	46	58.2
	No	33	41.7
UCSF criteria	Yes	51	64.6
	No	28	35.4
HBsAg (+)	Yes	65	82.3
	No	14	17.7
AFP (ng/ml)	>400	20	25.3
	≤400	59	74.7
TNM stage	I	10	12.7
	II	23	29.1
	III-IV	46	58.2
Pretransplantation treatment	Yes	51	64.6
	No	28	35.4
RFA only	Yes	18	22.8
	No	61	77.2
Recurrence	Yes	20	25.3
	No	59	74.7

AFP: alpha-fetoprotein; CTC: circulating tumor cells; HBsAg: hepatitis B surface antigen; HCC: hepatocellular carcinoma; MVI: microvascular invasions; PVT: portal vein thrombosis; RFA: radiofrequency ablation; UCSF: University of California San Francisco.